• 1
    zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events of carcinogenesis. J Natl Cancer Inst 2000; 92: 6908.
  • 2
    zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev 2002; 2: 34250.
  • 3
    Clemens M, Goss P. Estrogen and the risk of breast cancer [erratum N Engl J Med 2002;344:1804]. N Engl J Med 2002; 344: 27685.
  • 4
    Gruber CJ, Tschuggel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002; 346: 34052.
  • 5
    Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, Shah KV, Meijer CJLM, Bosch FX. Role of parity and human papillomavirus in cervical cancer: the IARC Multicentric Case-Control Study. Lancet 2002; 359: 1093101.
  • 6
    Moreno V, Bosch FX, Munoz N, Meijer CJLM, Shah KV, Walboomers JMM, Herrero R, Franceschi S. Effect of oral contraceptives on risks of cervical cancer in women with human papillomavirus infection: the IARC Multicentric Case-Control Study. Lancet 2002; 359: 108592.
  • 7
    Lacey JV, Brinton LA, Abbas FM, Barnes WA, Gravitt PE, Greenberg MD, Greene SM, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Silverberg SG, et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 1999; 8: 107985.
  • 8
    Lacey JV, Brinton LA, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Kurman RJ, Hildesheim A. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2000; 77: 14954.
  • 9
    Madeleine MM, Daling JR, Schwartz SM, Shera K, McKnight B, Carter JJ, Wipf GC, Critchlow CW, McDougall JK, Porter P, Galloway DA. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev 2001; 10: 1717.
  • 10
    O'Connor M, Chan S-Y, Bernard H-U. Transcription factor binding sites in the long control region of genital HPVs. In: MyersG, BernardH-U, DeliusH, BakerC, IcenogelJ, HalpernA, WheelerC, eds. Human papillomaviruses 1995—a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos: Los Alamos National Laboratory, 1995. III- 2140.
  • 11
    Gloss B, Bernard HU, Seedorf K, Klock G. The upstream regulatory region of the human papillomavirus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBO J 1987; 6: 373543.
  • 12
    Chan WK, Klock G, Bernard HU. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol 1989; 63: 32619.
  • 13
    Mittal R, Pater A, Pater MM. Multiple human papillomavirus type 16 glucocorticoid response elements functional for transformation, transient expression, and DNA–protein interactions. J Virol 1999; 67: 56569.
  • 14
    Khare S, Pater MM, Tang SC, Pater A. Effect of glucocorticoid hormones on viral gene expression, growth, and dysplastic differentiation in HPV16-immortalized ectocervical cells. Exp Cell Res 1997; 232: 35360.
  • 15
    Chong T, Chan WK, Bernard HU. Transcriptional activation of human papillomavirus 16 by nuclear factor 1, AP1, steroid receptors and a possible novel transcription factor, PVF: a model for the composition of genital papillomavirus enhancers. Nucleic Acids Res 1990; 18: 46570.
  • 16
    Khare S, Kumar KU, Tang SC, Pater MM, Pater A. Up-regulation of hormone response of human papillomavirus type 16 expression and increased DNA–protein binding by consensus mutations of viral glucocorticoid response elements. J Med Virol 1996; 50: 25462.
  • 17
    Mittal R, Kumar KU, Pater A, Pater MM. Differential regulation by c-jun and c-fos protooncogenes of hormone response from composite glucocorticoid response element in human papilloma virus type 16 regulatory region. Mol Endocrinol 1994; 8: 17018.
  • 18
    Bromberg-White JL, Meyers C. The upstream regulatory region of human papillomavirus type 31 is insensitive to glucocorticoid induction. J Virol 2002; 76: 970215.
  • 19
    Chen Y-H, Huang L-H, Chen T-M. Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophys Res Commun 1996; 224: 6519.
  • 20
    Crook T, Storey A, Almond N, Osborn K, Crawford L. Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells. Proc Natl Acad Sci USA 1988; 85: 88204.
  • 21
    Pater A, Bayatpur M, Pater MM. Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. Am J Obstet Gynecol 1990; 1099103.
  • 22
    Pater MM, Hughes GA, Hyslop DE, Nakshatri H, Pater A. Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papillomavirus DNA. Nature 1988; 335: 8325.
  • 23
    Dürst M, Gallahan D, Jay G, Rhim JS. Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papillomavirus type 16 and an activated ras oncogene. Virology 1989; 173: 76771.
  • 24
    Pater MM, Pater A. RU486 inhibits glucocorticoid hormone-dependent oncogenesis by human papillomavirus type 16 DNA. Virology 1991; 183: 799802.
  • 25
    Crook T, Banks L, Smith K, Crawford L. Amplification and overexpression of c-myc proto-oncogene correlate with the loss of glucocorticoid dependence in rodent cells transformed by human papillomavirus type 16. Mol Carcinog 1989; 2: 30813.
  • 26
    Pater A, Belaguli NS, Pater MM. Glucocorticoid requirement for growth of human papillomavirus 16–transformed primary rat kidney epithelial cells: correlation of development of hormone resistance with viral RNA expression and processing. Cancer Res 1993; 53: 44326.
  • 27
    Pater A, Belaguli NS, Gardner HA, Mithal A, Pater MM. Glucocorticoid-dependent transformation by human papillomavirus type 16 E7 coding and 3′ noncoding sequences. Virology 1992; 188: 36972.
  • 28
    Yuan F, Auborn K, James C. Altered growth and viral gene expression in human papillomavirus type 16–containing cancer cell lines treated with progesterone. Cancer Invest 1999; 17: 1929.
  • 29
    Khan MA, Canhoto AJ, Housley PR, Creek KE, Pirisi L. Glucocorticoids stimulate growth of human papillomavirus type 16 (HPV-16)–immortalized human keratinocytes and support HPV-16-mediated immortalization without affecting the levels of HPV-16 E6/E7 mRNA. Exp Cell Res 1997; 236: 30410.
  • 30
    Nonogaki H, Fujii S, Konishi I, Nanbu Y, Ozaki Y, Ishikawa Y, Mori T. Estrogen receptor localization in normal and neoplastic epithelium of the uterine cervix. Cancer 1990; 66: 26207.
  • 31
    Monsonego J, Magdelenat H, Catalan F, Coscas Y, Zerat L, Sastre X. Estrogen and progesterone receptors in cervical papillomavirus related lesions. Int J Cancer 1991; 48: 5339.
  • 32
    Auborn KJ, Woodworth C, DiPaolo JA, Bradlow HL. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int J Cancer 1991; 49: 8679.
  • 33
    Salazar EL, Mercado E, Sojo I, Salcedo M. Relationship between estradiol 16 alpha-hydroxylation and human papillomavirus infection in cervical cell transformation. Gynecol Endocrinol 2001; 15: 33540.
  • 34
    Mittal R, Tsutsumi K, Pater A, Pater MM. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet Gynecol 1993; 81: 512.
  • 35
    Piccini A, Storey A, Romanos M, Banks L. Regulation of human papillomavirus type 16 DNA replication by E2, glucocorticoid hormone and epidermal growth factor. J Gen Virol 1997; 78: 196370.
  • 36
    zur Hausen H. Papillomavirus infections—a major cause of human cancers. Biochim Biophys Acta 1996; 1288: F5578.
  • 37
    Qin X-Q, Livingston DM, Kaelin WG Jr, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994; 91: 1091822.
  • 38
    Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 1994; 91: 36026.
  • 39
    Sears RC, Nevins JR. Signaling networks that links cell proliferation and cell fate. J Biol Chem 2002; 277: 1161720.
  • 40
    Massimi P, Pim D, Bertoli C, Bouvard V, Banks L. Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene 1999; 18: 774854.
  • 41
    Webster K, Parish J, Pandya M, Stern PL, Clarke AR, Gaston K. The HPV-16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 2000; 275: 8794.
  • 42
    Webster K, Taylor A, Gaston K. Oestrogen and progesterone increase the levels of apoptosis induced by human papillomavirus type 16 E2 and E7 proteins. J Gen Virol 2001; 82: 20113.
  • 43
    Newfield L, Bradlow HL, Sepkovic DW, Auborn K. Estrogen metabolism and the malignant potential of human papillomavirus immortalized keratinocytes. Proc Soc Exp Biol Med 1998; 217: 3226.
  • 44
    Chen DZ, Qi M, Auborn KJ, Carter TH. Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV-16-transgenic preneoplastic cervical epithelium. J Nutr 2001; 131: 3294302.
  • 45
    Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, Mayeaux EJ, Tucker A, Turbat-Herrera EA, Mathis JM. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000; 78: 1239.
  • 46
    Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res 2000; 60: 126775.
  • 47
    Taylor JA, Tewari K, Liao SY, Hughes CCW, Villarreal LP. Immunohistochemical analysis, human papillomavirus DNA detection, hormonal manipulation, and exogenous gene expression of normal and dysplastic human cervical epithelium in severe combined immunodeficiency mice. J Virol 1999; 73: 51448.
  • 48
    Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci USA 1996; 93: 29305.
  • 49
    Qi M, Chen D, Liu K, Auborn KJ. N-6 polyunsaturated fatty acids increase skin but not cervical cancer in human papillomavirus 16 transgenic mice. Cancer Res 2002; 62: 4336.
  • 50
    Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E, Jansen-Durr P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci USA 1999; 96: 12916.
  • 51
    Jin L, Qi M, Chen DZ, Anderson A, Yang GY, Arbeit JM, Auborn KJ. Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV-16) transgenic mice. Cancer Res 1999; 59: 39917.
  • 52
    Morales-Peza N, Auewarakul P, Juárez V, Garcia-Carrancá A, Cid-Arregui A. In vivo tissue-specific regulation of the human papillomavirus type 18 early promoter by estrogen, progesterone and their antagonists. Virology 2002; 294: 13540.
  • 53
    Critchlow C, Wolner-Hanssen P, Eschenbach DA, Kiviat NB, Koutsky LA, Stevens CE, Holmes KK. Determinants of cervical ectopia and of cervicitis: age, oral contraception specific cervical infection, smoking, and douching. Am J Obstet Gynecol 1995; 173: 53443.
  • 54
    Sun Q, Tang SC, Pater MM, Pater A. Different HPV E6/E7 oncogene expression patterns in epithelia reconstructed from HPV16-immortalized human endocervical cells and genital keratinocytes. Oncogene 1997; 15: 2399408.
  • 55
    Ylitalo N, Sorensen P, Josefsson A, Frisch M, Sparén P, Pontén J, Gyllenstein U, Melbye M, Adami H-O. Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. Int J Cancer 1999; 81: 35765.
  • 56
    Moscicki A-B, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, Darragh T, Palefsky J. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285: 29953002.